InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.082 0.003 (3.53%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$40 Notification of cessation of securities - IMU 12 Jan 2026 5:03PM $0.340 $0.082 fallen by 75.88%
$40 Application for quotation of securities - IMU 8 Jan 2026 6:05PM $0.345 $0.082 fallen by 76.23%
$40 Executive Update 2 Jan 2026 3:46PM $0.390 $0.082 fallen by 78.97%
$40 Cleansing Notice 23 Dec 2025 12:40PM $0.305 $0.082 fallen by 73.11%
$40 Application for quotation of securities - IMU 22 Dec 2025 5:49PM $0.315 $0.082 fallen by 73.97%
$40 Notification regarding unquoted securities - IMU 22 Dec 2025 4:37PM $0.315 $0.082 fallen by 73.97%
$40 Notification of cessation of securities - IMU 22 Dec 2025 11:45AM $0.310 $0.082 fallen by 73.55%
$40 Notification regarding unquoted securities - IMU 22 Dec 2025 10:18AM $0.313 $0.082 fallen by 73.76%
$40 Application for quotation of securities - IMU 19 Dec 2025 4:33PM $0.305 $0.082 fallen by 73.11%
$40 Change of Director's Interest Notice x5 19 Dec 2025 4:30PM $0.305 $0.082 fallen by 73.11%
$40 Proposed issue of securities - IMU 19 Dec 2025 9:15AM $0.305 $0.082 fallen by 73.11%
$40 Amendment of Convertible Notes 18 Dec 2025 5:43PM $0.305 $0.082 fallen by 73.11%
$40 Letter to Shareholders 17 Dec 2025 10:28AM $0.310 $0.082 fallen by 73.55%
$40 Investor Webinar FDA Meeting 8 Dec 2025 9:02AM $0.320 $0.082 fallen by 74.38%
$40 FDA Supports Strategy Toward Registration for Azer-cel 8 Dec 2025 8:49AM $0.320 $0.082 fallen by 74.38%
$40 Overall Response Rate increases to 82% in azer-cel trial 1 Dec 2025 3:05PM $0.330 $0.082 fallen by 75.15%
$40 Investor Webinar JW Therapeutics Collaboration 27 Nov 2025 9:10AM $0.325 $0.082 fallen by 74.77%
$40 Strategic Collaboration with JW Therapeutics 27 Nov 2025 9:08AM $0.325 $0.082 fallen by 74.77%
$40 Results of 2025 Annual General Meeting 13 Nov 2025 1:58PM $0.315 $0.082 fallen by 73.97%
$40 Annual General Meeting Presentation 13 Nov 2025 8:24AM $0.330 $0.082 fallen by 75.15%
$40 Becoming a substantial holder 4 Nov 2025 12:15PM $0.365 $0.082 fallen by 77.53%
$40 Investor webinar on CAR T naive lymphomas & ASH presentation 4 Nov 2025 10:22AM $0.345 $0.082 fallen by 76.23%
$40 Imugene selected for Oral Presentation at ASH Annual Meeting 4 Nov 2025 10:16AM $0.345 $0.082 fallen by 76.23%
$40 Cleansing Notice 3 Nov 2025 7:49PM $0.350 $0.082 fallen by 76.57%
$40 Application for quotation of securities - IMU 3 Nov 2025 7:42PM $0.350 $0.082 fallen by 76.57%

76 - 100 of 1186 results

Page 4 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.